Patents by Inventor Enrique Iglesias Perez
Enrique Iglesias Perez has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20230405106Abstract: The present invention provides a chimeric protein that has a modular structure and comprises a receptor binding domain (RBD) from the spike protein (S) of coronaviruses, a segment able to bind the core antigen from the Hepatitis B Virus (HBcAg), a segment including six consecutive histidine residues (HHHHHH), and two spacer segments. In this chimeric protein the aforementioned segments are arranged in a specific order, and the protein is able to form hybrid nanoparticles with HBcAg. The chimeric protein is part of vaccine compositions used for the prevention of coronavirus infections. Therefore, the invention discloses a method for the prevention of coronavirus infections, whereby a vaccine composition comprising said chimeric protein is administered.Type: ApplicationFiled: November 3, 2021Publication date: December 21, 2023Inventors: Glay CHINEA SANTIAGO, Alejandro Miguel MARTÍN DUNN, Diamilé GONZÁLEZ ROCHE, Miladys LIMONTA FERNÁNDEZ, Enrique IGLESIAS PÉREZ, Mónica BEQUET ROMERO, Héctor SANTANA MILIAN, Gabriel J. MARQUEZ PERERA, Alexis MUSACCHIO LASA, Ania CABRALES RICO, Gerardo Enrique GUILLEN NIETO, Marta AYALA ÁVILA, Eulogio PIMENTEL VAZQUEZ, Gertrudis ROJAS DORANTES, Vivian HUERTA GALINDO
-
Patent number: 11759517Abstract: This invention reveals the pharmaceutical composition that includes the surface antigen (HBsAg) of the hepatitis B virus (HBV) and the antigen of the nucleocapsid (or core, HBcAg) of the same virus. The HBcAg of this composition contains messenger ribonucleic acid (mRNA) at a proportion of over 45% of the total amount of ribonucleic acid (RNA) in this antigen. Because of the changes in the constitution of the antigens forming it, the composition of the invention is useful for the prevention or treatment of chronic hepatitis B. It also covers the use of this pharmaceutical composition in the production of a drug for immuno-prophylaxis or immunotherapy against HBV infection, and its use to increase the immune response against an additional antigen that is co-administered with the mixture of these antigens.Type: GrantFiled: March 8, 2022Date of Patent: September 19, 2023Assignee: CENTRO DE INGENIERÍA GENÉTICA Y BIOTECNOLOGÍAInventors: Julio César Aguilar Rubido, Yadira Lobaina Mato, Enrique Iglesias Perez, Eduardo Pentón Arias, Gerardo Enrique Guillén Nieto, Jorge Agustin Aguiar Santiago, Sonia Gonzalez Blanco, Jorge Valdes Hernandez, Mariela Vazquez Catillo
-
Patent number: 11491218Abstract: This invention reveals the pharmaceutical composition that includes the surface antigen (HBsAg) of the hepatitis B virus (HBV) and the antigen of the nucleocapsid (or core, HBcAg) of the same virus. The HBcAg of this composition contains messenger ribonucleic acid (mRNA) at a proportion of over 45% of the total amount of ribonucleic acid (RNA) in this antigen. Because of the changes in the constitution of the antigens forming it, the composition of the invention is useful for the prevention or treatment of chronic hepatitis B. It also covers the use of this pharmaceutical composition in the production of a drug for immuno-prophylaxis or immunotherapy against HBV infection, and its use to increase the immune response against an additional antigen that is co-administered with the mixture of these antigens.Type: GrantFiled: March 14, 2017Date of Patent: November 8, 2022Assignee: CENTRO DE INGENIERÍA GENÉTICA Y BIOTECNOLOGÍAInventors: Julio César Aguilar Rubido, Yadira Lobaina Mato, Enrique Iglesias Perez, Eduardo Pentón Arias, Gerardo Enrique Guillén Nieto, Jorge Agustín Aguiar Santiago, Sonia Gonzalez Blanco, Jorge Valdes Hernandez, Mariela Vazquez Castillo
-
Publication number: 20220193228Abstract: This invention reveals the pharmaceutical composition that includes the surface antigen (HBsAg) of the hepatitis B virus (HBV) and the antigen of the nucleocapsid (or core, HBcAg) of the same virus. The HBcAg of this composition contains messenger ribonucleic acid (mRNA) at a proportion of over 45% of the total amount of ribonucleic acid (RNA) in this antigen. Because of the changes in the constitution of the antigens forming it, the composition of the invention is useful for the prevention or treatment of chronic hepatitis B. It also covers the use of this pharmaceutical composition in the production of a drug for immuno-prophylaxis or immunotherapy against HBV infection, and its use to increase the immune response against an additional antigen that is co-administered with the mixture of these antigens.Type: ApplicationFiled: March 8, 2022Publication date: June 23, 2022Inventors: Julio César AGUILAR RUBIDO, Yadira LOBAINA MATO, Enrique IGLESIAS PEREZ, Eduardo PENTÓN ARIAS, Gerardo Enrique GUILLÉN NIETO, Jorge Agustín, Sonia GONZALEZ BLANCO, Jorge, Mariela
-
Publication number: 20200297840Abstract: This invention reveals the pharmaceutical composition that includes the surface antigen (HBsAg) of the hepatitis B virus (HBV) and the antigen of the nucleocapsid (or core, HBcAg) of the same virus. The HBcAg of this composition contains messenger ribonucleic acid (mRNA) at a proportion of over 45% of the total amount of ribonucleic acid (RNA) in this antigen. Because of the changes in the constitution of the antigens forming it, the composition of the invention is useful for the prevention or treatment of chronic hepatitis B. It also covers the use of this pharmaceutical composition in the production of a drug for immuno-prophylaxis or immunotherapy against HBV infection, and its use to increase the immune response against an additional antigen that is co-administered with the mixture of these antigens.Type: ApplicationFiled: March 14, 2017Publication date: September 24, 2020Inventors: Julio César AGUILAR RUBIDO, Yadira LOBAINA MATO, Enrique IGLESIAS PEREZ, Eduardo PENTÓN ARIAS, Gerardo Enrique GUILLÉN NIETO, Jorge Agustín AGUIAR SANTIAGO, Sonia GONZALEZ BLANCO, Jorge VALDES HERNANDEZ, Mariela VAZQUEZ CASTILLO
-
Publication number: 20080280354Abstract: The invention relates to HIV chimeric gene formed by the union of fragments of different genes of said virus, wherein said fragments contains epitopes for cytotoxic T cells (CTL) or HIV-1 auxiliary T cells, which are presented by a wide range of antigens of type Major Histocompatibility Complex (HLA-I). Recombinant poxviruses are obtained from said genes, which are useful for prophylactic and therapeutic vaccination against HIV/AIDS infections, are capable of generating a protective immune cell response in vaccinated laboratory animals and are recognized by the CTL lymphocytes of HIV/AIDS patients.Type: ApplicationFiled: July 14, 2006Publication date: November 13, 2008Inventors: Enrique Iglesias Perez, Dania M. Vazquez Blomquist, Carlos A. Duarte Cano
-
Patent number: 7374766Abstract: The present invention is related to the branch of medicine, particularly to the new formulations of vaccine antigens. The technical objective pursued with the present invention is, precisely, the development of formulations that are able to enhance the immune response to mucosally administered antigens, minimising the number of compounds in the formulation and generating strong mucosal and systemic responses through a synergic interaction between the antigens in the formulation. These formulations enable: a) to broaden the spectrum of the anti-hepatitis B immune response, containing as main compounds HBsAg and HBcAg, b) to enhance the response against HBsAg with a viral nucleocapsid c) to generate combined vaccines through the mucosal route with HBsAg as a central antigen. Stabilizers and preservatives can be introduced. The formulations of this invention can be applied in the pharmaceutical industry as human or veterinary vaccine formulations.Type: GrantFiled: December 1, 1999Date of Patent: May 20, 2008Assignee: Centro de Ingenieria Genetic y BiotechnologiaInventors: Julio César Aguilar Rubido, Daniel O. Palenzuela Gardón, Verena L. Muzio González, Gerardo E. Guillén Nieto, Eduardo Pentón Arias, Dagmara Pichardo Díaz, Enrique Iglesias Perez
-
Patent number: 7318927Abstract: The invention relates to HIV chimeric gene formed by the union of fragments of different genes of said virus, wherein said fragments contains epitopes for cytotoxic T cells (CTL) or HIV-1 auxiliary T cells, which are presented by a wide range of antigens of type Major Histocompatibility Complex (HLA-I). Recombinant poxviruses are obtained from said genes, which are useful for prophylactic and therapeutic vaccination against HIV/AIDS infections, are capable of generating a protective immune cell response in vaccinated laboratory animals and are recognized by the CTL lymphocytes of HIV/AIDS patients.Type: GrantFiled: February 22, 2002Date of Patent: January 15, 2008Assignee: Centro de Ingenieria Genetica y BiotecnologiaInventors: Enrique Iglesias Perez, Dania M. Vazquez Blomquist, Carlos A. Duarte Cano
-
Publication number: 20070275012Abstract: The present invention is related with the field of therapeutic vaccines against pathogens causing chronic diseases. It comprises the use in therapy of formulations containing the Hepatitis B surface antigen (HBsAg) as the main compound. The HBsAg is produced as a recombinant product in Picchia pastoris. The formulations of the present invention also comprise the combination of the Hepatitis B surface antigen and other coadministered antigens. The resulting formulations are able to generate potent lymphoprolipherative and cytotoxic responses apart from a remarkable response of specific antibodies, which make them very effective in the treatment of such diseases.Type: ApplicationFiled: October 20, 2004Publication date: November 29, 2007Inventors: Julio Aguilar Rubido, Enrique Iglesias Perez, Yadira Lobaina Mato, Daymir Garcia Gonzalez, Verena Muzio Gonzalez, Gerardo Guillen Nieto, Nelson Acosta Rivero, Raimundo Ubieta Gomez, Julio Alvarez Obregon, Santiago Duenas Carrera, Carlos Duarte Cano, Peter Vanlandshoot, Luis Herrera Martinez
-
Publication number: 20040073008Abstract: The invention relates to HIV chimeric gene formed by the union of fragments of different genes of said virus, wherein said fragments contains epitopes for cytotoxic T cells (CTL) or HIV-1 auxiliary T cells, which are presented by a wide range of antigens of type Major Histocompatibility Complex (HLA-I). Recombinant poxviruses are obtained from said genes, which are useful for prophylactic and therapeutic vaccination against HIV/AIDS infections, are capable of generating a protective immune cell response in vaccinated laboratory animals and are recognized by the CTL lymphocytes of HIV/AIDS patients.Type: ApplicationFiled: August 27, 2003Publication date: April 15, 2004Inventors: Enrique Iglesias Perez, Dania M Vazquez Blomquist, Carlos A Duarte Cano
-
Patent number: 6358933Abstract: The present invention is for a formulation comprising a nucleic acid vaccine and an immunoenhancing amount of acemannan, whereby the acemannan enhances immune response, in a host, to the vaccine. The present invention is also for a method of enhancing the immune response of a host to a nucleic acid vaccine by administering a formulation comprising a nucleic acid vaccine and acemannan.Type: GrantFiled: May 5, 2000Date of Patent: March 19, 2002Assignee: Centro de Ingenieria Genetica Y BiotechologiaInventors: Julio Cesar Aguilar Rubido, Verena Lucila Muzio Gonzalez, Gerardo Enrique Guillen Nieto, Eduardo Penton Arias, Maria de Jesus Leal Angulo, Dagmara Pichardo Diaz, Enrique Iglesias Perez, Antonieta Herrera Buch, Belquis Sandez Oquendo, Alexis Musacchio Lasa, Diogenes Quitana Vazquez, Lissere Crombet Menedez
-
Patent number: 6355414Abstract: The present invention is related to the field of medicine, particularly to the use of new adjuvant formulations with vaccine antigens. The technical objective pursued with this invention is, precisely, the development of formulations that are able to increase and/or modulate the immune response of the organism to vaccine antigens in the serum and the mucous lining. With this aim, a formulation was developed that contained as the main components the surface antigen of the hepatitis B virus and the acemannan in adequate proportions. As an extension of this result, formulations were developed in which a) HBsAg was used as the homologous or heterologous antigen carrier b) delivery systems of particulated antigens and c) soluble antigens, combined with the acemannan in specific proportions. The formulations of this invention are applicable in the pharmaceutical industry as vaccine formulations for human and veterinary use.Type: GrantFiled: January 6, 2000Date of Patent: March 12, 2002Assignee: Centro de Ingenieria Genetica y BiotechnologiaInventors: Julio Cesar Aguilar Rubido, Verena Lucila Muzio Gonzalez, Maria de Jesus Leal Angulo, Gerardo Enrique Guillen Nieto, Eduardo Penton Arias, Gloria Veliz Rios, Dagmara Pichardo Diaz, Antonieta Herrera Buch, Enrique Iglesias Perez, Luis Javier Cruz Ricondo, Tania Carmenate Portilla, Cirse Mesa Pardillo, Maydel Hechavarria Gay, Maylin Diaz Martinez, Juan Joel Madrazo Piñol